Aug 27, 2008 by Brian Orelli, PhDAnother FDA Setback for Johnson & JohnsonThe company has to wait for an approval of its extended-release schizophrenia drug.
Aug 27, 2008 by Brian Orelli, PhDAmylin Answers, Investors PanicA conference call about side effects doesn't have the desired effect.
Aug 26, 2008 by Brian Orelli, PhDBaxter Ready to Sop Up Additional RevenueThe health-care giant licenses a surgical sponge in clinical development.
Aug 26, 2008 by Brian Orelli, PhDRapid Exchange of FireCompetitors try to block Abbott's patent extension.
Aug 25, 2008 by Brian Orelli, PhDHealth Insurers Head to ChinaEvery other industry's doing it -- why not health care?
Aug 22, 2008 by Brian Orelli, PhDDon't Worry About Vytorin's Cancer RiskCongress' ramblings are much ado about nothing.
Aug 22, 2008 by Brian Orelli, PhDAbbott Tries a Crash DietThe health-care conglomerate is cutting jobs in its diagnostic testing division.
Aug 21, 2008 by Brian Orelli, PhDA Gardasil GotchaUh-oh. Merck's HPV vaccine may not be cost-effective.
Aug 21, 2008 by Brian Orelli, PhDJohnson & Johnson Gets RejectedThe FDA rejects Johnson & Johnson's antibiotic.
Aug 20, 2008 by Brian Orelli, PhDA Moooving AcquisitionEli Lilly buys Monsanto's cow hormone business.
Aug 20, 2008 by Brian Orelli, PhDMedtronic Muddles ThroughThe medical device maker manages double-digit growth in a tough market.
Aug 19, 2008 by Brian Orelli, PhDYour House Is Not an Emergency FundDon't count on your HELOC to bail you out.
Aug 19, 2008 by Brian Orelli, PhDToo Much Punishment for AmylinSeveral more pancreatitis cases cause investors to panic.
Aug 18, 2008 by Brian Orelli, PhDFoolish Forecast: Taking Medtronic to HeartViews you can use to get clues on tomorrow's news.
Aug 15, 2008 by Brian Orelli, PhDSyneron Medical's Bipolar GrowthInternational sales are keeping the company afloat.
Aug 14, 2008 by Brian Orelli, PhDWald Equation Won't Derail Boston ScientificThe Wall Street Journal reanalyzes data, but will the FDA care?
Aug 12, 2008 by Brian Orelli, PhDDon't Discard OmrixIt found a way to sell stuff it used to throw away.
Aug 6, 2008 by Brian Orelli, PhDIllumina Grabs Some CashWith the stock hitting 52-week highs, what did investors expect to happen?
